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ABSTRACT:

Correlation of Dynamic Contrast Enhanced MRI Imaging Characteristics with
Gene Expression Profiles in Renal Cell Carcinoma

Essmaeel H. Abdel-Dayem1, Stephen Pautler2, Jonathan Walker2, Janies R. Vasselli2,
Michael V. Knopp1, Richard M. Klausner2, W. Mareston Linehan2, and Peter L. Choyke1
Diagnostic Radiology Department, Warren Grant Magnuson Clinical Center1
and the Urologic Oncology Branch, National Cancer Institute2,
National Institutes of Health, Bethesda, Maryland

Introduction:
Multiple clinical studies have correlated the degree of tumor vascularity on
histopathology to disease progression and patient prognosis. These studies have
important implications for clinical care. Imaging techniques designed to evaluate
angiogenesis will aid in the characterization and staging of tumors, and with the advent of
anti-angiogenic treatments, will help the clinician choose optimal treatments and evaluate
tumor response. Before this can become a reality, imaging phenotypes must be correlated
with histopathology and gene expression. Dynamic Contrast Enhanced MRI (DCE-MRI)
has been shown to be a useful method for imaging tumor vascularity. For this reason we
have undertaken a pilot study to identify differentially expressed genes between areas of
high and low enhancement on DCE-MRI in human renal cancers.

Methods:
Patients with sporadic renal cell cancers scheduled for nephrectomy at the NIH
Clinical Center received pre-operative DCE-MRI to evaluate tumor vascularity. Areas of
high and low contrast enhancement were selected by a staff radiologist for immediate
post-surgical tissue procurement. The tumors were bivalved post-operatively and the
areas of the tumor correlating to the areas selected on the DCE-MRI study were
collected. mRNA from the samples was isolated for cDNA microarray analysis and qRTPCR. Immunohistochemical staining for VEGF and CD31 was also performed.

Results:
Statistical analysis of paired enhancing and non-enhancing samples from the same
tumor using a Wilcoxon matched pairs signed rank test identified 242 of 8579 genes as
most significantly different between the two groups. Due to the sample size, the highest
tier of significance had a p-value of 0.0625. Among these genes are VEGFB, a known
angiogenic factor, and HIF 1 a, a gene intimately involved in oxygen sensing and
implicated in Von-Hippel Lindau (VHL) disease, the most common hereditary form of
renal cell carcinoma. Also of interest, 11 ribosomal genes were contained in the list of
242 genes (4.5%) as compared to 0.4% ribosomal genes on the entire microarray chip,
11.4 times the expected number by chance alone. This higher percentage of ribosomal
proteins along with the presence of several genes involved with glucose metabolism may
indicate a state of increased translational activity and metabolism in the enhancing areas
of the tumor. Immunohistochemical staining for VEGF and CD31 showed no correlation

with contrast enhancement profiles. qRT-PCR analysis showed increased VEGF
expression in the enhancing regions of tumors in 4 of 5 cases studied.

Discussion:
In summary, DCE-MRI appears to have the most utility as a general method of
monitoring functional tumor vascularity and cellular metabolism rather than a means of
monitoring specific molecular events. The initial results of this pilot study are promising
and merit expansion of the study to include more patients. There will need to be some
modification of the protocol to address some of the obstacles inherent in working with
human tissue. This experimental paradigm is important in bridging the gap between
imaging technology and studies correlating histopathology with prognosis and identifies
potential pitfalls in this process.
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INTRODUCTION

The revolution in molecular and cellular biology, the unraveling of the human
genome, the ability to decipher the molecular pathways that belie many of the diseases
that plague humanity today have changed the manner in which we practice medicine.
With this explosion of information regarding the molecular basis of disease, a need has
emerged to develop non-invasive, high resolution methods to image these processes. In
vivo molecular imaging has been identified by the National Institutes of Health and the
medical research community at large as a unique opportunity not only to study diseases
non-invasively at the molecular level, but also to help translate bench top research into
clinical advances in diagnosis, management, and treatment. Molecular imaging
techniques designed to advance biomedical research today, may become the diagnostic
modalities of tomorrow. With substantial funding now available in this budding field,
investigators from many different disciplines including molecular biologists, imaging
scientists, medical physicists, combinatorial and organic chemists, and clinicians from
almost all specialties have come together to help realize the promise of this endeavor.
At present, our diagnostic assessment of disease is based on anatomic or
physiologic changes that are often a late manifestation of the molecular changes that
underlie disease. Direct visualization of these molecular events has the potential to
directly affect patient care by allowing much earlier detection of disease. It may be
possible to image molecular changes in the pre-symptomatic or even pre-disease state
which would allow us to intervene at an early stage when we are more likely to provide
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effective treatment that can change the outcome. By directly imaging the underlying
alterations of disease, we may also potentially be able to directly image the effects of
therapy and, consequently, play a direct role in determining the effectiveness of treatment
shortly after the initiation of therapy. An important corollary to this is that this type of
work lends itself to the discovery of new molecular targets for improved and more
specific treatments and imaging reagents. Of all the molecular processes that imaging
scientists have attempted to detect and monitor in vivo, perhaps the most studied is
angiogenesis.

Imaging Angiogenesis
Angiogenesis is a complex process critical to the growth and metastasis of
malignant tumors. The term angiogenesis was first used to describe the growth of
endothelial sprouts from preexisting postcapillary venules, but in more recent literature,
the term has been used to describe the maturation of primitive vascular networks into
more complex ones. Angiogenesis occurs physiologically during embryonic
development, the female reproductive cycle, wound healing, and hair growth. In 1971,
however, Folkman et al. proposed that tumor growth and metastasis are angiogenesis
dependent processes, and that blocking angiogenesis could be an effective strategy to
arrest tumor growth.1 In 1976, Gullino et al. showed that cells in pre-cancerous tissue
acquire angiogenic capacity on their way to becoming malignant tumors.2 The
development of these concepts prompted an intensive search for pro- and anti-angiogenic
molecules. The idea of the “angiogenic switch” is now widely accepted and that the
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relative amounts of pro-angiogenic and anti-angiogenic molecules determines whether or
not the chemical balance is tipped towards or away from angiogenesis.
The emergence of angiogenesis as an important target for cancer therapy has led
to an increased research effort targeted at understanding the mechanisms underlying the
development, maintenance, and destruction of tumor vasculature. With the evaluation of
numerous anti-angiogenic agents in clinical trials, the adaptation and validation of
molecular imaging techniques for monitoring angiogenesis has been in great demand.
The need for surrogate markers to evaluate drug effects has been highlighted by studies
involving tumors with very gradual regression rates where treatment response can only be
seen after several months.3 4 It is clear that imaging physiologic or molecular markers
may be the best method to evaluate response. Several imaging techniques, in particular
functional MR imaging, nuclear, and optical techniques are available for studying the
angiogenic state of tumor microvasculature.
Several approaches to imaging angiogenesis have been based upon specific
imaging probes to markers expressed on the altered nonendothelial surface of tumor
vessels.^ Since these markers may also represent the targets of new treatments, it is an
ideal imaging scenario. The utility of imaging at the same target is clear and may allow
for the earliest target assessment possible. This is important since noticeable effects at
this level may predate phenotypic effects by up to weeks or months. Unfortunately, due
to practical limitations with signal to noise and imaging molecule delivery, the
implementation of angiogenesis directed molecular imaging might not extend beyond
highly specialized clinical trials. In this light, imaging modalities that evaluate
angiogenesis at a functional level may prove to be more feasible.
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Dynamic Contrast Enhanced MRI (DCE-MRI)
Magnetic resonance imaging can be used experimentally to characterize
microvasculature and provide information about tumor microvessel structure and
function. While it is possible to use MR imaging probes directed towards targets involved
in angiogenesis, most MR modalities in use give functional information about the
angiogenic state in a tissue of interest. In general these techniques rely on first pass or
equilibrium contrast media enhancement. Physiologic parameters that can be extracted
through pharmacokinetic modeling include flow, perfusion, permeability, and vascular
structure.
MRI methods of assessing vascular characteristics have a number of advantages
over other imaging modalities such as positron emission tomography (PET), single
photon emission computed tomography (SPECT), and ultrasound (US). MRI is more
readily available than PET and specialized ultrasound equipment. It is minimally invasive
and does not involve radiation exposure. Data acquisition is quick and can be
incorporated into routine imaging studies. Furthermore, MRI maintains the highest
potential spatial resolution of the listed imaging modalities and is sensitive to a number of
different contrast mechanisms including blood flow, microvessel permeability and size,
tissue hypoxia, and metabolism. These studies when integrated can offer a more detailed
picture of the tissue microenvironment.
MR techniques can be classified as nonenhanced and contrast media enhanced
methods.6 The second group can be subcategorized based on the type of contrast medium
utilized. The first category is low molecular weight agents (<1000 Da) that rapidly
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diffuse into the extracellular fluid space (ECF). The second utilizes high molecular
weight contrast agents (>30,000 Da) intended to be retained in the intravascular space
due to their low propensity to diffuse out into the ECF. For these reasons, these contrast
agents are also called macromolecular contrast media (MCMM) or blood pool agents.
The final category involves contrast agents engineered to accumulate at sites of high
concentrations of angiogenesis mediating molecules. These are highly specialized
contrast agents that are currently under development and it will be some time before they
are available for clinical trials.
Of the types of contrast media mentioned here, low molecular weight agents have
been studied the most and have been utilized in multiple animal and clinical studies. This
experience has helped us understand the kinetics of this type of contrast agent against the
backdrop of several underlying pathophysiological processes. This knowledge is critical
for the proper application of functional angiogenic imaging and the standardization of
kinetic parameters for purposes of reporting.

Pathophysiologic Basis for Contrast Enhancement
As previously stated, studies have shown that the ability of some tumors to switch
on the angiogenic process is an essential step towards tumor growth and metastases. The
low molecular weight contrast agents used in dynamic MR act as makeshift probes for
tumor angiogenesis. The contrast agent travels through the vascular system, reaches the
neoplastic tissue bed, and begins to extravasate from the tumor vasculature, accumulating
in the extracellular space of the tissue and subsequently rediffuses back into the vascular
system with eventual elimination by the urinary system. It is postulated that contrast
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agents cross permeable tumor vessels via cell structures termed vesiculo-vacuolar
organelles (VVOs).7 VVOs are clusters of interconnecting uncoated vesicles and
vacuoles that can span the thickness of vascular endothelium in a tumor providing a
potential “pore” in the vascular endothelium. The characteristic increase in tumor
vascular permeability is most likely attributable to the upregulation of WO function. To
support this idea, vascular endothelial growth factor staining has been observed in the
VVOs of tumor associated microvascular endothelial cells.
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The correlation between the intensity of enhancement and the leakiness of this
pathological vasculature is essential to the clinical utility of DCE-MRI. This observation
has been made by several groups of investigators who showed that the intensity of
enhancement is related to the vascular density within the tissue.4 Differences in the
contrast enhancement pattern have also been shown to correlate with specific
histopathological properties of tumors.10 Histological studies have found that
microvascular density determined by CD31 staining was higher in malignant tissues than
in normal parenchyma, but that there may also be an overlap with benign lesions, in
particular inflammatory and proliferative processes.

Certain vascular permeability

factors have also been implicated as additional explanatory factors that can determine
MR signal enhancement. In a study by Knopp et al, MR vascular permeability, measured
as the efflux rate constant (k2i), closely correlated with tissue vascular endothelial growth
factor (VEGF) expression, a potent vascular permeability factor.13 In this study, breast
tumors without significant VEGF expression showed a linear correlation of k2i and
micro vessel density (MVD). Once tissue VEGF staining became more prominent, k2i
increased rapidly, independent of MVD. In a similar histological study involving cervical
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cancer, Knopp et al. were not able to show this same correlation between k2i and VEGF
staining, but instead showed a correlation with MVD regardless of the level of VEGF
expression.14 While the results of these studies are somewhat discordant, the role of the
VEGF family of genes in determining microvascular permeability is supported by several
studies showing reductions in kinetic parameters after treatment with antiangiogenics
including VEGF tyrosine kinase inhibitors in humans.15 While the list of modulators of
angiogenesis grows, it is clear from these studies that functional angiogenic imaging can
not only help validate studies of angiogenic and anti-angiogenic agents, but may help in
the identification of new molecular targets for treatment.

Standardization and Quantification of DCE-MRI
The utility of DCE-MRI is increased by the fact that it can be performed on a
standard 1.5 T clinical MRI system. The most important criterion for this imaging
protocol is that there be a verified linear relationship between concentration of contrast
media and signal intensity. After this relationship is established, the quality of the
imaging protocol lies in a trade-off between spatial and temporal resolution. It is
important that the temporal resolution be fast enough to detect several imaging points
during the initial pass of contrast media through the tissue bed. A good guideline for this
is that at least three 3-dimensional volumes should be acquired during the administration
of the contrast agent when first pass kinetics are being visualized. This can be
accomplished either by shortening the acquisition time by sacrificing spatial resolution,
or by lengthening the duration of the contrast injection. Another important consideration
is the establishment of a baseline for the determination of time intensity curves. This can
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be achieved by acquiring several volumes before contrast administration. This will later
allow greater reliability in the quantification of contrast enhancement. Finally, it is
important that the total acquisition time be sufficiently long. While the determination of
this time is related to the speed of contrast administration, it is also a function of the
pathophysiological enhancement characteristics of the target tissue. Extended imaging is
needed to assess the contrast washout characteristics of the tissue, which can help
differentiate between malignant and benign masses. For this reason, long acquisition
times (at least 5 times the length of the contrast administration time) can greatly enhance
the utility of the study. It is also useful to examine contrast enhancement of some of the
major arteries within an image to help establish the quality of the contrast injection. The
arterial enhancement pattern can be used to verify the timing and dosage of a contrast
injection and can also be used as an in vivo standard or an “input function” to relate
tissue enhancement with contrast administration.16
Once the images are collected, the next step is to select regions of interest and
create time-intensity curves for contrast enhancement. While the shape of these timeintensity curves can provide a great deal of information about the tissue of interest, they
are extremely sensitive to patient motion. The motion of tissue in and out of the plane of
the slice can affect the validity of the generated curve. For this reason, patient
positioning, proper volume selection, and the use of positioning devices and compression
belts can greatly increase the quality of the study.
There are three features that should be considered in any time-intensity curve: the
initial rate of enhancement (k2i), the time and intensity of the peak enhancement or
amplitude of the curve (A), and the washout or contrast elimination after peak
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enhancement (kei).17 Pharmacokinetic modeling, in our case a two compartment model
proposed by Brix et al, is used to help relate these quantitative parameters with
physiologic concepts (figure 3).

18

These models can be used to overlay calculated

parameter images over high-resolution two-dimensional images to generate colorencoded maps of tumor perfusion and vascular permeability. This is particularly
important in these types of studies because of the large numbers of images generated that
would be extremely time consuming to analyze without the aid of parameter maps (figure
4).19 These parameter maps not only simplify the analysis of this data, but also render this
data readily shared between clinicians.

Clinical Applications
Because DCE-MRI can be performed on most clinical strength magnets and
requires no special equipment, it has lent itself to investigation in multiple clinical
studies. Perhaps the most promising application for this modality is in lesion
characterization. Observations from multiple studies have shown that malignant tissues
generally have a steep, high intensity curve expressed mathematically by a high k2i. This
has been studied most extensively in the breast and, subsequently, DCE-MRI may
eventually have a role in screening patients at high risk for breast cancer. However,
because there is an overlap between the enhancement patterns of benign and malignant
breast lesions, the sensitivity of breast MRI may be high, but the specificity may not be as
good.20
Contrast enhancement patterns on dynamic imaging have also been shown to
predict prognosis. In patients with cervical cancer, it was observed that tumors with a
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rapid initial rate of enhancement were more likely to carry a poorer prognosis for patients
despite exhibiting a better response to radiotherapy.
DCE-MRI can also help predict or monitor the effects of a number of different
treatments. Studies have been performed looking at DCE-MRI in the neoadjuvant
chemotherapy of breast cancer and sarcomas of the bone. For example, in breast cancer,
it has been found that a decrease in vascular permeability can be seen with a response to
chemotherapy, and that the absence of a decrease in permeability after only 1 or 2 cycles
of treatment can predict a treatment nonresponder. “ A number of studies have also
reported on the utility of DCE-MRI in monitoring the effects of anti-angiogenic
therapies. In these studies, a successful response to therapy resulted in a decrease in
tumor enhancement whether it was evaluated in a quantitative or a semi-quantitative
fashion.23 24
Tumor response to therapy as measured by DCE-MRI is relatively non-specific to
treatment modality. This observation may indicate that tumor cell kill, no matter how it is
achieved, should ultimately result in vascular compromise. While this allows DCE-MRI
to be used to assess treatment response at an early stage, it may mean that it is limited in
its ability to indicate to us the process at the source of the tumor response. Still, the
observation of the phenotype of vascularity and changes in this phenotype can help us
design experiments to search for the molecular changes associated with it. DCE-MRI as a
phenotypic measurement of vascularity can help us direct not only a targeted search, but
also genome wide screening for novel genes regulating tumor angiogenesis and response
to therapy.
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STATEMENT OF PURPOSE AND HYPOTHESIS

Clinically there have been a number of studies relating the degree of
.

•

.

.

.

TC

vascularization on direct tissue examination to tumor progression and patient prognosis.
These studies have important implications for clinical care. Functional characterization of
tumor neovasculature can aid in tumor detection, characterization, and staging.
Furthermore, with a multitude of anti-angiogenic therapies in clinical trials, imaging
techniques designed to evaluate angiogenesis can help the clinician choose the most
appropriate treatment, optimize the treatment dose, and detect early responses or failures.
Further clinical implications include the identification of angiogenic molecular targets
within tumors and the possible development of individualized image based drug delivery
systems. Still, before this can become a reality, functional imaging phenotype must be
correlated with histopathology and gene expression.
As stated previously, several studies have attempted, some successfully to
validate dynamic T1-contrast enhanced MR kinetic parameters with markers of
angiogenesis in human tumors. In general, these studies have looked at differences
between patients with tumors exhibiting different patterns of contrast enhancement. In
our experience, we have found many tumors to be extremely heterogeneous in nature,
with parts of a single tumor showing high levels of contrast enhancement while others
showing very little enhancement at all. This observation raises the question as to whether
or not these areas exhibiting different MRI contrast enhancement phenotypes within the
same tumor are differentially expressing angiogenic genes that are soliciting
neovascularity. If this is the case, there should be differential gene expression when
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examining these different areas of the same tumor. This would have important
implications for the classification of tumors through biopsies since biopsies in many
cases only sample a small amount of tissue within a tumor that may not be exhibiting
malignant features. This type of functional microvascular imaging may help direct tissue
sampling for more accurate clinical prognoses and for purposes of tissue procurement in
angiogenesis research.
To address this question, we have undertaken a pilot study of kidney cancers
using pre-operative Dynamic Contrast Enhanced MRI (DCE-MRI) followed by
procurement of tumor tissue from areas with different enhancement characteristics within
the same tumor. The samples were run on cDNA microarrays to identify differences in
gene expression profiles between enhancing and non-enhancing regions (figure 1).

Hypothesis:
Areas of high and low enhancement on Dynamic Contrast Enhanced MRI (DCEMRI) of renal cell carcinomas have differentially expressed genes that can be
identified by cDNA microarray analysis.
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METHODS

Clinical Material.
Subjects for the study were chosen from amongst patients receiving their care at
the NIH’s Urologic Oncology Branch for sporadic renal cell carcinoma. Patients who
were to receive total nephrectomies were consented and scheduled for pre-operative
dynamic contrast-enhanced MRI 1-2 days prior to total nephrectomy. All nephrectomies
were performed at the National Institutes of Health Clinical Center by urologists in the
Urologic Oncology Branch of the National Cancer Institute.

Dynamic Contrast Enhanced Magnetic Resonance Imaging
Imaging was performed using a 1.5 T clinical imaging system (GE medical
systems, Milwaukee, WI). The dynamic portion of the abdominal MR imaging protocol
included a static 3D-FSPGR pre- and post-contrast acquisition followed by a dynamic
image series which was acquired coronally as 23 volumes each containing 12 - 4mm
slices through the kidney of interest with 30 seconds between the start of each volume
acquisition (TR = 7.8, TE = 4.2, Flip = 25°, NEX = 0.5, 256 x 192 matrix). Patients were
asked to hold their breath for 15 seconds while the image was acquired and were allowed
to breathe for another 15 seconds before the start of the next cycle. The coronal view was
chosen for easier correlation of the imaging data with the gross specimen post-surgically
and because it posed fewer problems with motion artifacts from inconsistent breath
holding during acquisition. After three to four volumes were acquired to establish a
baseline, O.lmmol/Kg Gadolinium-diethylene triamine pentaaceticacid (Gd-DTPA) was
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injected slowly over the course of 1 minute and the flow of contrast was followed out for
the remainder of the 10-minute scan (figure 2).
Contrast enhancement was quantified using a two compartment model described
by Brix et al. that describes the enhancement as a the parameter amplitude (A),
redistribution rate constant (k2i [min

]), and elimination rate constant (kei [min

])

Using this model, pharmacokinetic analysis was performed using in house software
written for IDL (author MVK). Time-intensity curves were generated for different
regions of interest (ROIs) and were fitted to the pharmacokinetic model. The maximal
amplitude of enhancement the tissue exchange rate constant (k2i) were calculated for
each pixel and were color coded to assist in the visualization of these parameters within
the tumor (figure 3). Based on these parametric maps and cinematic views of the tumor
during contrast enhancement, areas of high and low enhancement were selected by a staff
radiologist for tissue procurement immediately post-operatively.

Tissue Procurement
Post-surgically, the tumors were bivalved and photographed to demonstrate
correlation between the imaging and the pathology before the previously selected regions
of the tumor were excised and frozen immediately in OCT compound. When excising the
selected regions of the tumor, care was taken to stay away from regions of gross necrosis
and to select areas that looked grossly viable. A sample of normal kidney was also
procured at this time and banked for future study.
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Microarray Procedures
Total RNA was isolated from the tumor samples by grinding the tissue fragments
into fine powder by mortar and pestle on dry ice, and homogenizing the powder in 5 ml
of TRIzol (Gibco BRL, Gaithersburg, MD). While this procedure yielded ample amounts
of a full range of RNA species as verified by gel electrophoresis, this total RNA resulted
in low signal intensities and an unacceptable amount of non-specific background. This
was most likely due to a low ratio of mRNA to ribosomal RNA. For this reason,
messenger RNA was isolated from total RNA with a Micro-Fastrak 2.0 kit (Invitrogen,
Carlsbad, CA) to improve the signal to noise ratio. Only very small amounts of mRNA
could be obtained from the total RNA using this process. For this reason, an amplification
step was added to maximize the signal intensity and reduce the amount of non-specific
background on the microarrays. Linear mRNA amplification has been shown to improve
the quality of cDNA microarrays without compromising the fidelity of the original
mRNA species isolated from the tumor.
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In the amplification step, the mRNA was reverse transcribed (RT) by priming
with oligo-dT, into single stranded DNA and double stranded DNA transcribed from a
primer added during the RT reaction.

One round of in-vitro transcription amplified

approximately 2ug of mRNA into 30 - lOOug of amplified mRNA. The amplified tumor
and normal mRNA were reverse transcribed incorporating a Cy3 (Green) labeled
thymidine into the newly formed DNA molecule. All tumor and normal DNA was
hybridized against a standard reference consisting of amplified mRNA from 6 pooled
tumor cell lines labeled with Cy5 (Red) onto the NCI 9,600 oncogene chip using the
Stratagene Fairplay® microarray kit.
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Data Analysis
The microarrays were scanned using a GenePix 4000 microarray scanner (Axon
Instruments, Foster City, CA) and analyzed using GenePix Pro 3.0 software. Spots were
excluded if there was an obvious problem with the hybridization or if the spot was
defective. Log base 2 -ratios of local background subtracted intensity levels were
analyzed. Log ratios were considered missing for spots with intensity less than 50 in both
channels (truncated at ±6) and if less than 50% of spots were not at least 1 SD above
background. A spot was filtered out from analysis if the log-ratio was missing in more
than 30% of the arrays. Log-ratios for each microarray were median centered to adjust for
dye bias and PMT settings.
The arrays were then loaded and stored in a database supported by the Center for
Information Technology at the National Institutes of Health. Statistical analysis was
performed with software developed by the National Human Genome Research Institute
(Bethesda, MD). The arrays were categorized as enhancing or non-enhancing and a
Wilcoxon Matched Pairs Signed-Rank test was run to compare data in the two groups.
This statistical test allowed the arrays to be analyzed in pairs from the same patient,
looking for differences in expression levels that are consistent across the patient
population while maintaining an internal control to cancel out normal variations between
individual patients.
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Immunohistochemical staining for VEGF and CD31
We performed immunohistochemical studies on 5 tumor pairs selected for the
quality of their imaging studies and microarray data. All samples were acquired
immediately post-operatively and frozen in OCT compound. The samples were cut in 6
pm sections and stored on slides at -80°C for staining. The tissue sections were stained
with VEGF and CD31 rabbit polyclonal antibodies (Dako, Carpinteria, CA ) at 1:200
dilution. Sections for immunostaining were treated with 3% hydrogen peroxide for 10
minutes to quench myeloperoxidase and then cleared in running water followed by a 5minute rinse in Tris-buffered saline (TBS) at a pH of 7.6. Slides were mounted on the
Dako Autostainer and incubated with antibody to VEGF (1 hour) and staining was
completed using the Dako Rabbit Envision Plus Kit (Dako, Carpinteria, CA). The
sections were removed from the Stainer and counterstained with a modified Mayer
hematoxylin followed by 10 dips in 0.3% ammonia water. Sections were rinsed in
running tap water and mounted with Immunmount (Harvey Instruments, Buffalo, NY).
Negative controls were run containing no antibody. Two sections through each tumor
were stained in this manner, and the degree of staining was assessed by a staff pathologist
at the NIH Clinical Center using a 0 to 3 scale with 3 being the strongest level of staining.

Quantitative Real-Time PCR (qRT-PCR) of tumor VEGF
qRT-PCR analysis was performed on the five tumor sets that were analyzed by
microarray. cDNA from the reverse transcription step of RNA amplification was banked
and used for the qRT-PCR studies. Primers and probes for VEGF were the standard
VEGF set from Applied Biosystems (Foster City, CA). (3-actin was amplified in the same
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tube with VEGF as a control and was used for purposes of normalization. Primer and
probe sets for (3-actin were also supplied by Applied Biosystems. Real time PCR
reactions for all samples were conducted in a volume of 25 pL using the Taq-Man qRTPCR kit (Applied Biosystems, Foster City, CA). Thermal cycler parameters were 2
minutes at 50°C, 10 minutes at 95°C, and 40 cycles each consisting of a 15 second
denaturing step at 95°C and a 1-minute annealing step at 60°C. All assays were performed
in duplicate or triplicate and the results reported as the mean. Standard curves were
generated and the relative expression levels normalized to P-actin levels for each sample.
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RESULTS

Dynamic Contrast Enhanced MR!:
A total of 10 patients were imaged between 8/16/2001 and 7/2/2002. Two of the
patients were excluded due to inadequate imaging exams, one was excluded due to the
high degree of necrosis at the time of tissue procurement, and two were excluded due to
insufficient amounts of RNA extracted for cDNA microarray. This left tumors from a
total of 5 patients that were successfully microarrayed.
All 5 cases showed heterogeneously enhancing tumors with distinct
pharmacokinetic regions within each tumor. Examples of two DCE-MRI studies are
shown in figures 5 and 6 along with the correlation of the image with the gross specimen
for tissue procurement.

Microarray Analysis and mRNA Expression Profiles

Microarrays were successfully performed on 5 patients, 4 with clear cell renal cell
carcinoma, and one with a collecting duct tumor. The quality and reproducibility of the
arrays was verified through scatter plots and multidimensional scaling. Three samples
were run in duplicate to check for reproducibility of arrays and the Pearson correlation
coefficient for theses samples on scatter plots were all >.90. The initial evaluation of the
tumor sets was done by scatter plot analysis to show outlying genes (Figure 7) before
evaluation with a Wilcoxon test. From the complete set of printed genes, 8,579 passed the
baseline quality control filtering criteria for spot size, intensity, signal to noise, and
presence in greater than 70% of the arrays. Wilcoxon match pairs signed rank test
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analysis identified 242 out of 8579 genes as the most significantly different between the
two groups. Due to the small sample size and the nature of the statistical analysis, the 242
genes identified as having the greatest significance could not achieve significance below
a p-value of 0.0625 (Figure 8). Among these genes are VEGF B, a known angiogenic
factor, and H1F la, a gene intimately involved in Von-Hippel Lindau Disease (VHL)
which is the most common form of hereditary RCC. Both of these genes are potential
prognostic markers for RCC and they are upregulated in the enhancing areas. Vascular
endothelial growth factor was not filtered out as differentially expressed in this set of
genes. Also of interest, 11 ribosomal genes were contained in the list of 242 genes (4.5%)
as compared to 0.4% ribosomal genes on the entire microarray chip, 11.4 times the
number expected by chance alone. This higher percentage of ribosomal proteins along
with the presence of several genes involved with glucose metabolism may indicate a state
of increased translational activity and metabolism in the enhancing areas of the tumor.

RT-PCR Analysis of VEGF Expression
When enhancing and non-enhancing samples were compared with regard to
VEGF expression as evaluated by RT-PCR, 4 of the 5 cases studied showed statistically
greater VEGF expression in the enhancing sample over the non-enhancing sample. The
results of these experiments are shown in the graphs below. While this data may be
suggestive of an increase in VEGF expression in enhancing areas, the low sample number
does not allow for the establishment of statistical significance.
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Figure 9. qRT-PCR of VEGF: Quantitative RT-PCR analysis of VEGF expression in
high flow (HF) and low flow (LF) regions of renal cell carcinomas as evaluated by DCEMRI. When possible, a sample of normal kidney was assayed from each patient for
comparison. Cases 1 through 4 show increased VEGF expression in the contrast
enhancing or high flow regions of the tumor while the final case shows very low VEGF
expression in the contrast-enhancing region.

Immunohistochemical Staining of VEGF
Histological examination of sections stained with VEGF antibodies showed no
correlation with contrast enhancement in the tumors examined. Of the 5 cases stained,
VEGF staining was rated higher in the enhancing sample in 2 of the 5 cases while the
non-enhancing sample showed a greater degree of VEGF staining in another 2 of the 5
cases. The last case showed minimal VEGF staining in both samples from that tumor.
The results are shown in table 1. The normal kidney sample from all cases did not stain
with the VEGF antibody. No difference was seen with hematoxylin staining between the
enhancing and non-enhancing samples from each tumor. Furthermore no association was
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seen between tissue enhancement on DCE-MRI and micro-vascular density as evaluated
byCD31 staining.

VEGF Staining
Sample
Case

1

Case 2

Case 3

Case 4

Case 5

HF

Rating

Focal

2

LF

Focal

1

Normal

Weak

0

HF

Focal

1

LF

Diffuse

2

Normal

Neg

0

HF

Focal

3

LF

Focal

1

HF

Neg

0

LF

Diffuse

2

Normal

Neg

0

HF

Neg

0

LF

Neg

0

Normal

Weak

0

Table 1. Immunohistochemical staining for VEGF: Two sections through each tumor
sample were stained with VEGF rabbit polyclonal antibody, and the degree of staining
was assessed by a staff pathologist at the NIE1 Clinical Center using a 0 to 3 scale with 3
being the strongest level of staining. HF represents the enhancing or high flow sample of
each tumor while LF represents the non-enhancing or low flow sample. No association is
seen between tissue enhancement on DCE-MRI and VEGF staining. Similar staining with
CD31 to evaluate micro-vessel density also showed no association with enhancement.
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DISCUSSION

Several studies have attempted, some successfully to validate dynamic Tlcontrast enhanced MR kinetic parameters with markers of angiogenesis in human tumors.
In general, these studies have looked at differences between patients with tumors
exhibiting different patterns of contrast enhancement. In our experience, we have found
many tumors to be extremely heterogeneous in nature, with parts of a single tumor
showing high levels of contrast enhancement while others showing very little
enhancement at all. As DCE-MRI evolves into an important tool for evaluating tumor
vasculature, the molecular mechanisms that underlie this enhancement heterogeneity
must be elucidated. This information will help us determine the significance of this
heterogeneity and whether or not it should be taken into account clinically when using
DCE-MRI to evaluate tumors and in tissue biopsies.
To our knowledge, this study is the first attempt to look for differences in mRNA
expression profiles based on intra-tumoral differences in contrast enhancement on
dynamic MRI in humans. The pharmacokinetic models used in DCE-MRI assume that
enhancement is dependent on the amount of functional tumor vasculature. For this reason
we had initially hypothesized that variations in contrast enhancement would be dependent
upon perfusion related phenomena based on the action of angiogenic factors. While this
was a pilot study to conceptually test this type of experimental paradigm in humans, the
preliminary results demonstrate several interesting observations and provide insight into
contrast enhancement heterogeneity on DCE-MRI.
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One of the most interesting findings is the disproportionately high number of
ribosomal genes in our microarray analysis. These increases in ribosomal gene
transcription may indicate an increased cellular demand for translational activity which is
typically seen in proliferating cell populations or cells stimulated by oxygenation,
nutrition, growth factors, or changes in temperature.

Thus, it is logical that areas of a

tumor with greater degrees of enhancement on DCE-MRI are receiving increased
oxygenation and nutrition and consequently show increased ribosomal transcription and
increased cellular activity. This observation was made by Costouros et al in a similar
experiment in an animal model.30 In this study, DCE-MRI was performed on murine
subcutaneous tumors and areas were chosen for laser capture microdissection, and
genetic profiling of tumor heterogeneity based on the pharmacokinetic parameters
observed. There was no evidence in this study of increased expression of proangiogenic
factors at the transcriptional level in either pharmacokinetic region, and there was no
difference observed between the regions on immunostaining with CD31, a measure of
microvessel density. However, the expression of ribosomal proteins was found to be
greatly increased in the enhancing areas implying increased protein translation and
increased cellular activity. Supporting this concept in our study are several genes
involved in glucose metabolism that are also upregulated in the enhancing regions of the
tumors. These include hexokinase 3, insulin receptors, glucose-6-phosphate transporter
gene, and pyruvate kinase. This is especially interesting considering there are studies that
31
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have correlated FDG hypermetabolism on PET with Gd-DTPA enhancing tumors/
The relative absence of angiogenic factors from the filtered microarray results
indicates that DCE-MRI appears to be most useful in evaluating functional tumor

26

vasculature and cellular metabolism rather than specific molecular events. With that said,
two genes from the list of 242 are particularly interesting from a molecular standpoint.
Vascular endothelial growth factor B (VEGF B) is a member of the VEGF family of
proangiogenic factors while hypoxia inducible factor la (HIF la) is an oxygen sensing
gene involved in the VHL pathway, the pathway implicated in most renal malignancies.
While multiple studies mentioned earlier were able to correlate VEGF expression with
contrast enhancement between tumors, VEGF expression alone could not explain
differences in contrast enhancement in the same tumor by immunostaining or qRT-PCR.
Further work may eventually point to an angiogenic factor or multiple factors as an
explanation for the observed heterogeneity within a tumor, but the relative absence of
pro-angiogenic factors from our analysis may imply post-transcriptional or even posttranslational modifications as an explanation. As such, proteomics may play an important
role in deciphering the underlying molecular processes.
Several more tumors will need to be studied before definitive genes of interest can
be identified by cDNA microarray and verified by quantitative methods such as RT-PCR
and immunohistochemistry. This pilot study has however identified many potential
pitfalls involved in working with human subjects that must be addressed before further
expansion of this work.
As mentioned earlier, one of the major difficulties inherent in imaging the kidneys
in this fashion is patient motion. DCE-MRI is exquisitely sensitive to motion in and out
of the slice of acquisition over the course of 10 minutes and several cycles of breath holds
by the patient. This type of artifact can greatly degrade the quality of the time-intensity
curves generated from these studies. For this reason, image homogeneity and the
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reduction of motion artifacts are even more critical for functional imaging than for
morphologic imaging. To help minimize this problem, we switched from a transaxial
view to a coronal view when acquiring images, which helped minimize motion in and out
of the plane of view. While there was slightly more translational motion observed in the
coronal plane, this is much easier to correct for than motion across slices. Several motion
correction algorithms were used in an attempt to correct for respiratory motion with little
success. While motion correction software is still not advanced enough to adequately
correct these high-resolution images, the use of positioning devices, compression belts,
and proper patient coaching to improve the consistency of their breath holds can
substantially improve image quality.
A second consideration in this type of study is the accuracy of image guided
tissue acquisition. Great care was taken to correlate the imaging study with the gross
specimen at the time of tissue acquisition. All the specimens were taken from cases
where the patient received a total nephrectomy. In this manner, the kidney could be
grossly oriented and selected landmarks identified within the tumor. Using these
landmarks, and keeping in mind the slice thickness of the MRI, the selected areas were
collected for analysis. Care was taken to select the larger volumes of enhancement within
the tumor to allow for error due to patient motion and human error. While this technique
of image guided tissue acquisition is crude at best, it represents the best method currently
available that maintains the standard of care for the patients in the protocol without
subjecting them to unnecessary interventional procedures. With the advent of MR guided
interventional procedures, other options include online DCE-MRI guided tissue biopsies.
Several groups are working on feducial markers that can be inserted at the time of
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imaging and used for motion correction and as a landmark for tissue acquisition. This
could conceptually be investigated as an adjunct to studies of interventional techniques
such as radio frequency ablation (RFA).
An added benefit to online interventional tissue acquisition schemes is that there
is no warm ischemia time to the organ of interest. The effect of warm ischemia on
microarray data is not well understood. Huang et al. attempted to quantify the effects of
warm ischemia on gene expression profiles in normal mucosa from human colon cancer
specimens.33 Their statistical models suggested that three patterns were induced by
ischemia. The first group consisting of 68.2% of evaluated genes showed an average 27%
increase in expression over 60 minutes from the 5-minute baseline. The second group
comprising 17.8% of evaluated genes showed only an average 12% increase or decrease
over 60 minutes. The final group comprising 13.4% of the evaluated genes showed the
most sensitivity with an average increase or decrease of 50% over 60 minutes. It is not
known exactly which genes on a given chip would belong to which group which is why it
is important to keep the warm ischemia time as low as possible. Warm ischemia time in
the samples in this study were estimated to be well over an hour, but because all
comparisons were made within the same set of tissue, the warm ischemia experienced by
all samples in a tissue set should be the same and the relative levels of RNA should be
preserved. Still, warm ischemia times should ideally be cut to below 20 minutes. We are
currently looking at surgical procedures developed for kidney harvesting for
transplantation that would reduce the warm ischemia time by preserving the renal pedicle
until near the end of the procedure.
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In summary, DCE-MRI appears to have the most utility as a general method of
monitoring functional tumor vascularity and cellular metabolism rather than a means of
monitoring specific molecular events. While the pharmacokinetic parameters measured
by DCE-MRI do not necessarily correlate with active angiogenesis, this does not
undermine its utility as a marker of response to antiangiogenic therapies as has been
shown in several studies mentioned earlier. In this situation, a change from a baseline
study can indicate a change in the vascular status of a tumor, but may not allow us to
draw conclusions about an active angiogenic process. Perhaps most importantly, in this
study we have demonstrated an experimental method of investigation to help understand
the underlying molecular mechanisms of imaging modalities by correlating their imaging
phenotypes with in vivo molecular events. The initial results of this pilot study are
promising and merit expansion of the study to include more patients. There will need to
be some modification of the protocol to address some of the obstacles inherent in
working with human tissue. This experimental paradigm is important in bridging the gap
between imaging technology and studies correlating histopathology with treatment and
prognosis. It is hoped that one day, functional tumor imaging will be able to provide the
clinician with the pathophysiological data necessary to direct patient care.
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Figure 1. Experimental Paradigm: To test the hypothesis that different rates of contrast
enhancement within kidney tumors reflect differences in gene expression, pre-operative
DCE-MR1 studies were performed on patients with sporadic renal cell carcinoma
scheduled for nephrectomy (a). The images were processed and time-intensity curves
were generated (b). These images were then used to guide sample procurement from
areas exhibiting high or low levels of enhancement (c). Finally, RNA was extracted from
part of these samples and analyzed using cDNA microarrays. A portion of the tissue
sample was retained for immunohistochemistry studies and cDNA was also banked for
qRT-PCR experiments.
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Figure 2. Dynamic Contrast Enhanced MRI (DCE-MRI): (a.) T1 weighted pre¬
contrast image of a patient with RCC of the right kidney, (b.) The tumor is seen to
enhance differentially after a slow injection of Gd-DTPA (arrow).
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Figure 3. Pharmacokinetic Modeling: (a.) Pharmacokinetic model for contrast
enhancement described by Brix et al. Enhancement here is described as a parameter
amplitude of the maximal signal intensity (A), a redistribution rate constant (k2i [min ” ]),
and an elimination rate constant (kei [min ']). (b.) A 16-color pixel-by-pixel parametric
color-coding scheme for amplitude and k2i parameters.
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Figure 4. Parametric Mapping: Average enhancement curve of a region of interest
(ROI ) through the center of a renal cell carcinoma with the corresponding parametric
color map. These types of images condense the large amount of data generated from
DCE-MRI studies into a single image that is easily analyzed and shared between
clinicians.
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Figure 5 Tissue
Procurement: T1
dynamic contrast
enhanced study of a
patient with renal cell
carcinoma. Tumor
heterogeneity is seen
on parametric mapping
of the tumor (top) and
on the raw images of
tumor enhancement
(middle). Correlation
of imaging with gross
pathology is shown
(bottom).
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Figure 6. Tissue
procurement: T1
dynamic contrast
enhanced study of a
patient with renal cell
carcinoma. Tumor
heterogeneity is seen
on parametric mapping
of the tumor (top) and
on the raw images of
tumor enhancement
(middle). Correlation
of imaging with gross
pathology is shown
(bottom).
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Figure 7. Scatter Plots: This example of a scatter plot shows the similarities between an
enhancing (y-axis) and non-enhancing (x-axis) sample from the same patient. While the
arrays appear very similar, there are several outliers beyond the parallel lines. While this
analysis is useful for identifying the genes that vary the most between two arrays from
the same person, it is not useful in identifying genes that vary slightly but consistently
between the enhancing and non-enhancing samples form each patient. For the second
type of analysis, a Wilcoxon test was used (See Data Analysis section).
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Figure 8. Analysis of cDNA microarray data: A Wilcoxon Matched Pairs Signed-Rank
test was run on 8579 genes to compare levels of expression in enhancing (group A) and
non-enhancing (group B) regions of a tumor. Samples are ordered so that the first sample
in group A was collected from the same tumor as the first sample in group B and so on.
The genes listed above are a sampling from 242 genes that achieved the highest tier of
significance (p value = 0.0625) VEGFB is one of many known angiogenic factors while
HIFla is a gene strongly linked to the development of renal cell carcinoma. Also within
this group are several genes involved in glucose metabolism and protein translation that
might indicate a higher level of translational activity in enhancing regions vs. non¬
enhancing regions. Other genes of interest not listed include several cell-cycle activators,
cell adhesion molecules, transcription factors, and apoptosis related genes. Differences
are displayed as log 2 ratios with negative values indicating increased expression in the
enhancing group. Spot images for the genes are displayed below the sample number on
the left.
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